Sanofi to acquire immuno-oncology company Synthorx for $2.5B
The San Diego-based biotech is developing IL-2 therapeutics for cancers as well as autoimmune disorders. Its lead candidate, THOR-707, is in a Phase I/II study in solid tumors.
The San Diego-based biotech is developing IL-2 therapeutics for cancers as well as autoimmune disorders. Its lead candidate, THOR-707, is in a Phase I/II study in solid tumors.
The timing of the filing appears to allay concerns that the FDA would require completion of a study evaluating the testicular safety of the drug, filgotinib, and thus push its launch date from 2020 to 2021-22, an analyst wrote.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Whether the FDA requires completion of a study to look at testicular toxicity before approval could dictate whether the drug launches next year or as late as 2022, an analyst wrote.
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK's venture capital arm, Celgene and others.
The company has been busy forming development and commercialization partnerships with other firms to develop antibodies in oncology and rheumatology.
The company will use funding to bring cell therapies into clinic in oncology and autoimmune indications.
Sangamo purchases 53 percent of France-based TxCell, will use zinc finger nuclease technology to develop CAR-Treg cells.
The unassuming llama may be the star of a new $75 million initial public offering, announced Monday by the Netherlands and Belgium-based biotech argenx.
Scripps spin-out aTyr Pharma announced Monday that it had rounded out its patent estate covering a full suite of signaling enzymes known as Physiocrines. It's good news for aTyr, but will the IP monopoly slow the wider field down?
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Aurinia Pharmaceuticals took an existing drug and made just one amino acid modification. Is it another meaningless iteration, or could this drug really deliver major gains in lupus nephritis?
On Thursday, Summit, New Jersey-based Celgene announced plans to acquire Delinia for an upfront $300 million and an additional $475 million in milestone-based payments. Delinia has a preclinical program that could be applied to a range of autoimmune diseases.